{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:50Z","timestamp":1790155730804,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytica Chimica Acta"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.aca.2018.02.022","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T23:13:34Z","timestamp":1519082014000},"page":"35-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Analysis of globotriaosylceramide (Gb 3 ) isoforms\/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography\/tandem mass spectrometry"],"prefix":"10.1016","volume":"1015","author":[{"given":"Amanda","family":"Toupin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Fran\u00e7oise","family":"Arthus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Abaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Auray-Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aca.2018.02.022_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","article-title":"Fabry's disease","volume":"344","author":"El-Abassi","year":"2014","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.aca.2018.02.022_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.aca.2018.02.022_bib3","series-title":"Fabry Disease","first-page":"1","author":"Germain","year":"2010"},{"key":"10.1016\/j.aca.2018.02.022_bib4","unstructured":"www.hgmd.org, Human Gene Mutation Database (HGMD)."},{"key":"10.1016\/j.aca.2018.02.022_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.aca.2018.02.022_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2015.11.018","article-title":"Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients","volume":"452","author":"Abaoui","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.aca.2018.02.022_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC\u2013MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.aca.2018.02.022_bib8","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2018.02.022_bib9","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb\u2083-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2018.02.022_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cphg.4","article-title":"Tandem mass spectrometry quantitation of lyso-Gb3 and six related analogs in plasma for Fabry disease patients","volume":"90","author":"Boutin","year":"2016","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"10.1016\/j.aca.2018.02.022_bib11","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2018.02.022_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13361-014-1060-3","article-title":"Metabolomic discovery of novel urinary Galabiosylceramide\u2009Analogs as Fabry disease biomarkers","volume":"26","author":"Boutin","year":"2015","journal-title":"J.\u00a0Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.aca.2018.02.022_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pediatrneurol.2016.07.001","article-title":"Fabry disease: a disorder of childhood onset","volume":"64","author":"Schiffmann","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.aca.2018.02.022_bib14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ymgme.2011.07.006","article-title":"Impact of growing up with Fabry disease on achievement of psychosocial milestones and quality of life","volume":"104","author":"Bouwman","year":"2011","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.aca.2018.02.022_bib15","series-title":"Cox, TM Fabry Disease: Perspectives from 5 Years of FOS","author":"Mehta","year":"2006"},{"key":"10.1016\/j.aca.2018.02.022_bib16","series-title":"Fabry Disease\u202f: a Metabolic Proteinuric Nephropathy","author":"Nu\u00f1ez","year":"2010"},{"key":"10.1016\/j.aca.2018.02.022_bib17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.aca.2018.02.022_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.aca.2018.02.022_bib19","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson-Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.aca.2018.02.022_bib20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.aca.2018.02.022_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10545-009-1055-6","article-title":"Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease","volume":"32","author":"Auray-Blais","year":"2009","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.aca.2018.02.022_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/207573","article-title":"Vascular tortuosities of the upper eyelid: a new clinical finding in Fabry patient screening","author":"Michaud","year":"2013","journal-title":"J.\u00a0Ophthalmol"},{"key":"10.1016\/j.aca.2018.02.022_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.aca.2018.02.022_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Auray-Blais","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.aca.2018.02.022_bib25","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease: yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.aca.2018.02.022_bib26","first-page":"1","article-title":"Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases","volume":"2","author":"Platt","year":"2004","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.aca.2018.02.022_bib27","article-title":"A\u00a0review of current and future treatment strategies for Fabry Disease\u202f: a model for treating lysosomal storage diseases","volume":"3","author":"Alipourfetrati","year":"2015","journal-title":"J.\u00a0Pharmacol. Clin. Toxicol"},{"key":"10.1016\/j.aca.2018.02.022_bib28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A\u00a0biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.aca.2018.02.022_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000448968","article-title":"Long term treatment with enzyme replacement therapy in patients with Fabry disease","volume":"134","author":"Oder","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.aca.2018.02.022_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","article-title":"A\u00a0revised home treatment algorithm for Fabry disease: influence of antibody formation","volume":"108","author":"Smid","year":"2013","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.aca.2018.02.022_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.aca.2018.02.022_bib32","series-title":"Canadian Fabry Disease Treatment Guidelines","author":"West","year":"2012"},{"key":"10.1016\/j.aca.2018.02.022_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.aca.2018.02.022_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","article-title":"Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry Registry","volume":"119","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.aca.2018.02.022_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.aca.2018.02.022_bib36","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2174\/092986712800784739","article-title":"Novel Gb3 isoforms detected in urine of Fabry disease patients: a metabolomic study","volume":"19","author":"Auray-Blais","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.aca.2018.02.022_bib37","doi-asserted-by":"crossref","DOI":"10.4155\/bio-2016-0116","article-title":"Relative distribution of Gb3 isoforms\/analogs in NOD\/SCID\/Fabry mice tissues determined by tandem mass spectrometry","volume":"8","author":"Proven\u00e7al","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.aca.2018.02.022_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.aca.2018.02.022_bib39","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A\u00a0metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2018.02.022_bib40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","article-title":"Cellular and tissue localization of globotriaosylceramide in Fabry disease","volume":"451","author":"Askari","year":"2007","journal-title":"Virchows Arch."},{"issue":"Suppl 1","key":"10.1016\/j.aca.2018.02.022_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10545-009-1060-9","article-title":"Leukocyte perturbation associated with Fabry disease","volume":"32","author":"Rozenfeld","year":"2009","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.aca.2018.02.022_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J.\u00a0Roy. Stat. Soc. B"},{"key":"10.1016\/j.aca.2018.02.022_bib43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.21500\/20112084.844","article-title":"Outliers detection and treatment: a review","volume":"3","author":"Cousineau","year":"2010","journal-title":"Int. J. Psychol. Res."},{"key":"10.1016\/j.aca.2018.02.022_bib44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson - Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.aca.2018.02.022_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","article-title":"Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry","volume":"438","author":"Auray-Blais","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.aca.2018.02.022_bib46","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0248-8663(00)00269-1","article-title":"La maladie de Fabry. Aspects cliniques et g\u00e9n\u00e9tiques. Perspectives th\u00e9rapeutiques","volume":"21","author":"Germain","year":"2000","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.aca.2018.02.022_bib47","series-title":"Le Syst\u00e8me Immunitaire","first-page":"406","author":"Parham","year":"2003"}],"container-title":["Analytica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000326701830237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000326701830237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:45:18Z","timestamp":1719827118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000326701830237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":47,"alternative-id":["S000326701830237X"],"URL":"https:\/\/doi.org\/10.1016\/j.aca.2018.02.022","relation":{},"ISSN":["0003-2670"],"issn-type":[{"value":"0003-2670","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of globotriaosylceramide (Gb3) isoforms\/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography\/tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Analytica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aca.2018.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}